Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study
Hypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these multiple conditions required separate medications for each disease, which may result in poor compliance and thus lead to possible treatment failure. Fixed-d...
Saved in:
| Published in | Clinical therapeutics Vol. 40; no. 5; pp. 676 - 691.e1 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.05.2018
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0149-2918 1879-114X 1879-114X |
| DOI | 10.1016/j.clinthera.2018.03.010 |
Cover
| Abstract | Hypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these multiple conditions required separate medications for each disease, which may result in poor compliance and thus lead to possible treatment failure. Fixed-dose combination (FDC) therapy with a single pill may be a solution in these situations.
This multicenter, 8-week, randomized, double-blind, Phase III study evaluated the efficacy and safety of FDC treatment with telmisartan (80 mg) and rosuvastatin calcium (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. Patients were randomly assigned to 4 groups: (1) FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin); (2) 80 mg of telmisartan; (3) 20 mg of rosuvastatin; or (4) placebo. After 8 weeks of treatment, the change in mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) between the FDC group and the rosuvastatin group, and the percent change in LDL-C between the FDC group and the telmisartan group, were compared.
A total of 210 patients were enrolled in the study (84 in the FDC group, 42 in the rosuvastatin group, 43 in the telmisartan group, and 41 in the placebo group). The reduction in blood pressure was significantly greater in the FDC group than in the rosuvastatin group after 8 weeks of treatment (least squares mean change from baseline, –16.1 [1.6] mm Hg vs –1.7 [2.2] mm Hg [P < 0.001] for MSSBP; –8.8 [1.0] mm Hg vs –1.6 [1.4] mm Hg [P < 0.001] for MSDBP). Least squares mean percent change in LDL-C from baseline was also significantly greater in the FDC group compared with the telmisartan group (–49.3% [2.2%] vs 1.5% [3.0%]; P < 0.001). FDC therapy also had a higher rate of achieving the treatment goal in both blood pressure (60% vs 45%; P = 0.024) and LDL-C (88.8% vs 16.3%; P < 0.001) compared with rosuvastatin or telmisartan alone, respectively. In regression analysis, higher baseline MSSBP, female sex, and lower body mass index were associated with increased reductions in MSSBP, whereas higher baseline LDL-C level and lower body mass index were associated with greater reductions in LDL-C. There were 48 adverse events in 36 patients (17.3% [36 of 208]), and 17 adverse drug reactions in 12 patients (5.8% [12 of 208]), indicating no significant differences in short-term safety among study groups.
Treatment with an FDC drug containing telmisartan and rosuvastatin showed similar efficacy in lowering blood pressure and LDL-C levels compared with that of each single drug. ClinicalTrials.gov identifier: NCT01914432. |
|---|---|
| AbstractList | Hypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these multiple conditions required separate medications for each disease, which may result in poor compliance and thus lead to possible treatment failure. Fixed-dose combination (FDC) therapy with a single pill may be a solution in these situations.
This multicenter, 8-week, randomized, double-blind, Phase III study evaluated the efficacy and safety of FDC treatment with telmisartan (80 mg) and rosuvastatin calcium (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. Patients were randomly assigned to 4 groups: (1) FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin); (2) 80 mg of telmisartan; (3) 20 mg of rosuvastatin; or (4) placebo. After 8 weeks of treatment, the change in mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) between the FDC group and the rosuvastatin group, and the percent change in LDL-C between the FDC group and the telmisartan group, were compared.
A total of 210 patients were enrolled in the study (84 in the FDC group, 42 in the rosuvastatin group, 43 in the telmisartan group, and 41 in the placebo group). The reduction in blood pressure was significantly greater in the FDC group than in the rosuvastatin group after 8 weeks of treatment (least squares mean change from baseline, -16.1 [1.6] mm Hg vs -1.7 [2.2] mm Hg [P < 0.001] for MSSBP; -8.8 [1.0] mm Hg vs -1.6 [1.4] mm Hg [P < 0.001] for MSDBP). Least squares mean percent change in LDL-C from baseline was also significantly greater in the FDC group compared with the telmisartan group (-49.3% [2.2%] vs 1.5% [3.0%]; P < 0.001). FDC therapy also had a higher rate of achieving the treatment goal in both blood pressure (60% vs 45%; P = 0.024) and LDL-C (88.8% vs 16.3%; P < 0.001) compared with rosuvastatin or telmisartan alone, respectively. In regression analysis, higher baseline MSSBP, female sex, and lower body mass index were associated with increased reductions in MSSBP, whereas higher baseline LDL-C level and lower body mass index were associated with greater reductions in LDL-C. There were 48 adverse events in 36 patients (17.3% [36 of 208]), and 17 adverse drug reactions in 12 patients (5.8% [12 of 208]), indicating no significant differences in short-term safety among study groups.
Treatment with an FDC drug containing telmisartan and rosuvastatin showed similar efficacy in lowering blood pressure and LDL-C levels compared with that of each single drug. ClinicalTrials.gov identifier: NCT01914432. Hypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these multiple conditions required separate medications for each disease, which may result in poor compliance and thus lead to possible treatment failure. Fixed-dose combination (FDC) therapy with a single pill may be a solution in these situations.PURPOSEHypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these multiple conditions required separate medications for each disease, which may result in poor compliance and thus lead to possible treatment failure. Fixed-dose combination (FDC) therapy with a single pill may be a solution in these situations.This multicenter, 8-week, randomized, double-blind, Phase III study evaluated the efficacy and safety of FDC treatment with telmisartan (80 mg) and rosuvastatin calcium (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. Patients were randomly assigned to 4 groups: (1) FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin); (2) 80 mg of telmisartan; (3) 20 mg of rosuvastatin; or (4) placebo. After 8 weeks of treatment, the change in mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) between the FDC group and the rosuvastatin group, and the percent change in LDL-C between the FDC group and the telmisartan group, were compared.METHODSThis multicenter, 8-week, randomized, double-blind, Phase III study evaluated the efficacy and safety of FDC treatment with telmisartan (80 mg) and rosuvastatin calcium (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. Patients were randomly assigned to 4 groups: (1) FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin); (2) 80 mg of telmisartan; (3) 20 mg of rosuvastatin; or (4) placebo. After 8 weeks of treatment, the change in mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) between the FDC group and the rosuvastatin group, and the percent change in LDL-C between the FDC group and the telmisartan group, were compared.A total of 210 patients were enrolled in the study (84 in the FDC group, 42 in the rosuvastatin group, 43 in the telmisartan group, and 41 in the placebo group). The reduction in blood pressure was significantly greater in the FDC group than in the rosuvastatin group after 8 weeks of treatment (least squares mean change from baseline, -16.1 [1.6] mm Hg vs -1.7 [2.2] mm Hg [P < 0.001] for MSSBP; -8.8 [1.0] mm Hg vs -1.6 [1.4] mm Hg [P < 0.001] for MSDBP). Least squares mean percent change in LDL-C from baseline was also significantly greater in the FDC group compared with the telmisartan group (-49.3% [2.2%] vs 1.5% [3.0%]; P < 0.001). FDC therapy also had a higher rate of achieving the treatment goal in both blood pressure (60% vs 45%; P = 0.024) and LDL-C (88.8% vs 16.3%; P < 0.001) compared with rosuvastatin or telmisartan alone, respectively. In regression analysis, higher baseline MSSBP, female sex, and lower body mass index were associated with increased reductions in MSSBP, whereas higher baseline LDL-C level and lower body mass index were associated with greater reductions in LDL-C. There were 48 adverse events in 36 patients (17.3% [36 of 208]), and 17 adverse drug reactions in 12 patients (5.8% [12 of 208]), indicating no significant differences in short-term safety among study groups.FINDINGSA total of 210 patients were enrolled in the study (84 in the FDC group, 42 in the rosuvastatin group, 43 in the telmisartan group, and 41 in the placebo group). The reduction in blood pressure was significantly greater in the FDC group than in the rosuvastatin group after 8 weeks of treatment (least squares mean change from baseline, -16.1 [1.6] mm Hg vs -1.7 [2.2] mm Hg [P < 0.001] for MSSBP; -8.8 [1.0] mm Hg vs -1.6 [1.4] mm Hg [P < 0.001] for MSDBP). Least squares mean percent change in LDL-C from baseline was also significantly greater in the FDC group compared with the telmisartan group (-49.3% [2.2%] vs 1.5% [3.0%]; P < 0.001). FDC therapy also had a higher rate of achieving the treatment goal in both blood pressure (60% vs 45%; P = 0.024) and LDL-C (88.8% vs 16.3%; P < 0.001) compared with rosuvastatin or telmisartan alone, respectively. In regression analysis, higher baseline MSSBP, female sex, and lower body mass index were associated with increased reductions in MSSBP, whereas higher baseline LDL-C level and lower body mass index were associated with greater reductions in LDL-C. There were 48 adverse events in 36 patients (17.3% [36 of 208]), and 17 adverse drug reactions in 12 patients (5.8% [12 of 208]), indicating no significant differences in short-term safety among study groups.Treatment with an FDC drug containing telmisartan and rosuvastatin showed similar efficacy in lowering blood pressure and LDL-C levels compared with that of each single drug. ClinicalTrials.gov identifier: NCT01914432.IMPLICATIONSTreatment with an FDC drug containing telmisartan and rosuvastatin showed similar efficacy in lowering blood pressure and LDL-C levels compared with that of each single drug. ClinicalTrials.gov identifier: NCT01914432. PurposeHypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these multiple conditions required separate medications for each disease, which may result in poor compliance and thus lead to possible treatment failure. Fixed-dose combination (FDC) therapy with a single pill may be a solution in these situations.MethodsThis multicenter, 8-week, randomized, double-blind, Phase III study evaluated the efficacy and safety of FDC treatment with telmisartan (80 mg) and rosuvastatin calcium (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. Patients were randomly assigned to 4 groups: (1) FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin); (2) 80 mg of telmisartan; (3) 20 mg of rosuvastatin; or (4) placebo. After 8 weeks of treatment, the change in mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) between the FDC group and the rosuvastatin group, and the percent change in LDL-C between the FDC group and the telmisartan group, were compared.FindingsA total of 210 patients were enrolled in the study (84 in the FDC group, 42 in the rosuvastatin group, 43 in the telmisartan group, and 41 in the placebo group). The reduction in blood pressure was significantly greater in the FDC group than in the rosuvastatin group after 8 weeks of treatment (least squares mean change from baseline, –16.1 [1.6] mm Hg vs –1.7 [2.2] mm Hg [P < 0.001] for MSSBP; –8.8 [1.0] mm Hg vs –1.6 [1.4] mm Hg [P < 0.001] for MSDBP). Least squares mean percent change in LDL-C from baseline was also significantly greater in the FDC group compared with the telmisartan group (–49.3% [2.2%] vs 1.5% [3.0%]; P < 0.001). FDC therapy also had a higher rate of achieving the treatment goal in both blood pressure (60% vs 45%; P = 0.024) and LDL-C (88.8% vs 16.3%; P < 0.001) compared with rosuvastatin or telmisartan alone, respectively. In regression analysis, higher baseline MSSBP, female sex, and lower body mass index were associated with increased reductions in MSSBP, whereas higher baseline LDL-C level and lower body mass index were associated with greater reductions in LDL-C. There were 48 adverse events in 36 patients (17.3% [36 of 208]), and 17 adverse drug reactions in 12 patients (5.8% [12 of 208]), indicating no significant differences in short-term safety among study groups.ImplicationsTreatment with an FDC drug containing telmisartan and rosuvastatin showed similar efficacy in lowering blood pressure and LDL-C levels compared with that of each single drug. ClinicalTrials.gov identifier: NCT01914432. AbstractPurposeHypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these multiple conditions required separate medications for each disease, which may result in poor compliance and thus lead to possible treatment failure. Fixed-dose combination (FDC) therapy with a single pill may be a solution in these situations. MethodsThis multicenter, 8-week, randomized, double-blind, Phase III study evaluated the efficacy and safety of FDC treatment with telmisartan (80 mg) and rosuvastatin calcium (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. Patients were randomly assigned to 4 groups: (1) FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin); (2) 80 mg of telmisartan; (3) 20 mg of rosuvastatin; or (4) placebo. After 8 weeks of treatment, the change in mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) between the FDC group and the rosuvastatin group, and the percent change in LDL-C between the FDC group and the telmisartan group, were compared. FindingsA total of 210 patients were enrolled in the study (84 in the FDC group, 42 in the rosuvastatin group, 43 in the telmisartan group, and 41 in the placebo group). The reduction in blood pressure was significantly greater in the FDC group than in the rosuvastatin group after 8 weeks of treatment (least squares mean change from baseline, –16.1 [1.6] mm Hg vs –1.7 [2.2] mm Hg [ P < 0.001] for MSSBP; –8.8 [1.0] mm Hg vs –1.6 [1.4] mm Hg [ P < 0.001] for MSDBP). Least squares mean percent change in LDL-C from baseline was also significantly greater in the FDC group compared with the telmisartan group (–49.3% [2.2%] vs 1.5% [3.0%]; P < 0.001). FDC therapy also had a higher rate of achieving the treatment goal in both blood pressure (60% vs 45%; P = 0.024) and LDL-C (88.8% vs 16.3%; P < 0.001) compared with rosuvastatin or telmisartan alone, respectively. In regression analysis, higher baseline MSSBP, female sex, and lower body mass index were associated with increased reductions in MSSBP, whereas higher baseline LDL-C level and lower body mass index were associated with greater reductions in LDL-C. There were 48 adverse events in 36 patients (17.3% [36 of 208]), and 17 adverse drug reactions in 12 patients (5.8% [12 of 208]), indicating no significant differences in short-term safety among study groups. ImplicationsTreatment with an FDC drug containing telmisartan and rosuvastatin showed similar efficacy in lowering blood pressure and LDL-C levels compared with that of each single drug. ClinicalTrials.gov identifier: NCT01914432. |
| Author | Baek, Sang Hong Han, Ki Hoon Shin, Eun Seok Han, Jung-Kyu Rhee, Moo-Yong Ihm, Sang-Hyun Lee, Byoung Kwon Hyon, Min-Su Jeong, Jin-Ok Kim, Soo-Joong Kim, Moo Hyun Yoo, Byung-Su Bae, Jang-Ho Kim, Sang Hyun Oh, Gyu Chul Choi, Young Jin Kim, Hyo-Soo Kim, Hyunsu Sung, Jung Hoon Hong, Kyung-Soon Cho, JangHyun Rhew, Jay Young Doh, Joon Hyung |
| Author_xml | – sequence: 1 givenname: Gyu Chul surname: Oh fullname: Oh, Gyu Chul organization: Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea – sequence: 2 givenname: Jung-Kyu surname: Han fullname: Han, Jung-Kyu organization: Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea – sequence: 3 givenname: Ki Hoon surname: Han fullname: Han, Ki Hoon organization: Division of Cardiology, Department of Internal Medicine, Asan Medical Center, Seoul, Republic of Korea – sequence: 4 givenname: Min-Su surname: Hyon fullname: Hyon, Min-Su organization: Division of Cardiology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea – sequence: 5 givenname: Joon Hyung surname: Doh fullname: Doh, Joon Hyung organization: Division of Cardiology, Department of Internal Medicine, Inje University Ilsan-Paik Hospital, Goyang, Republic of Korea – sequence: 6 givenname: Moo Hyun surname: Kim fullname: Kim, Moo Hyun organization: Division of Cardiology, Department of Internal Medicine, Dong-A University Hospital, Busan, Republic of Korea – sequence: 7 givenname: Jin-Ok surname: Jeong fullname: Jeong, Jin-Ok organization: Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Daejon, Republic of Korea – sequence: 8 givenname: Jang-Ho surname: Bae fullname: Bae, Jang-Ho organization: Division of Cardiology, Heart Center, Konyang University Hospital, Daejon, Republic of Korea – sequence: 9 givenname: Sang Hyun surname: Kim fullname: Kim, Sang Hyun organization: Division of Cardiology, Department of Internal Medicine, Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Republic of Korea – sequence: 10 givenname: Byung-Su surname: Yoo fullname: Yoo, Byung-Su organization: Division of Cardiology, Department of Internal Medicine, Wonju Christian Hospital, Wonju, Republic of Korea – sequence: 11 givenname: Sang Hong surname: Baek fullname: Baek, Sang Hong organization: Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Seoul, Republic of Korea – sequence: 12 givenname: Moo-Yong surname: Rhee fullname: Rhee, Moo-Yong organization: Division of Cardiology, Department of Internal Medicine, DongGuk University International Hospital, Goyang, Republic of Korea – sequence: 13 givenname: Sang-Hyun surname: Ihm fullname: Ihm, Sang-Hyun organization: Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, Bucheon, Republic of Korea – sequence: 14 givenname: Jung Hoon surname: Sung fullname: Sung, Jung Hoon organization: Department of Cardiology, CHA Bundang Medical Center, Seongnam, Republic of Korea – sequence: 15 givenname: Young Jin surname: Choi fullname: Choi, Young Jin organization: Department of Cardiology, Sejong General Hospital, Bucheon, Republic of Korea – sequence: 16 givenname: Soo-Joong surname: Kim fullname: Kim, Soo-Joong organization: Division of Cardiology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea – sequence: 17 givenname: Kyung-Soon surname: Hong fullname: Hong, Kyung-Soon organization: Division of Cardiology, Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea – sequence: 18 givenname: Byoung Kwon surname: Lee fullname: Lee, Byoung Kwon organization: Division of Cardiology, Department of Internal Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea – sequence: 19 givenname: JangHyun surname: Cho fullname: Cho, JangHyun organization: Department of Cardiology, Heart Center, Saint Carollo Hospital, Sun-cheon, Republic of Korea – sequence: 20 givenname: Eun Seok surname: Shin fullname: Shin, Eun Seok organization: Division of Cardiology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, Republic of Korea – sequence: 21 givenname: Jay Young surname: Rhew fullname: Rhew, Jay Young organization: Division of Cardiology, Department of Internal Medicine, Presbyterian Medical Center, Jeonju, Republic of Korea – sequence: 22 givenname: Hyunsu surname: Kim fullname: Kim, Hyunsu organization: Division of Cardiology, Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea – sequence: 23 givenname: Hyo-Soo surname: Kim fullname: Kim, Hyo-Soo email: hyosoo@snu.ac.kr organization: Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29673890$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkttrFDEUxkep2Is--a4BXyrsrElmOhdBpfRiFyuW7hbtU8gmJ2y2M8maZIrjX2-m2_ahIBYCk0l-33eSk2872TDWQJK8IXhMMCneL8ei0SYswPExxaQa42yMCX6abJGqrFNC8p8byRYmeZ3SmlSbybb3S4xxVu_R58kmrYsyq2q89eTVkVJacNEjbiSacgWhR1ahY_0bZCqtB3Rg27k2PGhr0GyouOrRDx0WaAZNqz13gZsb9bn13TX3IaIGxfHVOohbZ_EfTPBr0Um_AhfA-MFuUB32vtErLaHV_AOaHZ1OZ_vp5QXajdM7-9TdWMedwVo526LLiwU370aIo29dE7SIFcCN0Hm0tK3-A3KE8pS7doQObTdvIJ3HhsXFs4YLmNtUWBOcbZoBPFvweM_JZIKmoZP9i-SZ4o2Hl7ffneTi-Gh2cJKefv8yOdg_TcUewSEtS5zPC5VLDDkplSqBloWoJOUUF7msixpUXVdAKeRKch57DgWmqsaSxlWV7SS7a9-Vs7868IHF-wpoGm7Adp5RTKu6pHleR_TtA3RpO2fi6SKVlTnJIxqp17dUN29BspXTLXc9u3vuCHxcAyI21DtQTOhw87LBcd0wgtkQL7Zk9_FiQ7wYzliMV9SXD_R3Jf6v3F8rITb0WoNjXsRUCJDagQhMWv0Ij08PPAYupre5gh78fUcI85RhNh3iP6SfVNkgL6LB538bPOoIfwED-BwD |
| CitedBy_id | crossref_primary_10_2139_ssrn_4022954 crossref_primary_10_1016_j_cpcardiol_2023_101735 crossref_primary_10_7759_cureus_29014 crossref_primary_10_1007_s00228_020_02965_2 crossref_primary_10_1016_j_saa_2023_122588 crossref_primary_10_2147_DDDT_S391288 crossref_primary_10_1016_j_cmpb_2022_107088 crossref_primary_10_3390_jcm12062377 crossref_primary_10_1093_eurjpc_zwae307 crossref_primary_10_1016_j_clinthera_2019_02_013 crossref_primary_10_1016_j_curtheres_2024_100735 crossref_primary_10_1016_j_vph_2021_106900 crossref_primary_10_7759_cureus_47032 crossref_primary_10_13005_ojc_390329 crossref_primary_10_1111_jch_13765 crossref_primary_10_1111_jch_14645 crossref_primary_10_2174_011573403X283174240110025442 crossref_primary_10_1002_cpdd_926 crossref_primary_10_1038_s41591_024_02896_w crossref_primary_10_1111_jch_14345 crossref_primary_10_1016_j_ijcard_2022_04_085 crossref_primary_10_1111_jch_13893 crossref_primary_10_1186_s43094_021_00369_2 |
| Cites_doi | 10.1161/01.HYP.0000123072.34629.57 10.1016/j.clinthera.2016.09.005 10.2337/dc10-2109 10.1177/0003319713512556 10.1136/bmj.326.7404.1423 10.1016/S0002-9149(99)80621-3 10.1097/MBP.0b013e32833c5722 10.1161/01.CIR.95.2.473 10.1081/JDI-56610 10.1136/bmj.c1197 10.1161/01.HYP.0000107251.49515.c2 10.1016/S0002-9149(03)00530-7 10.1001/jama.2013.277064 10.1016/j.jacc.2014.08.021 10.1056/NEJMoa0807646 10.1038/sj.jhh.1000925 10.2147/DDDT.S112873 10.1161/01.CIR.0000127955.36250.65 10.2147/VHRM.S3662 10.1038/sj.jhh.1002036 10.1016/j.clinthera.2010.03.018 10.1016/j.clinthera.2016.06.011 10.1161/circ.106.25.3143 10.1016/S0140-6736(03)12948-0 10.1253/circj.CJ-13-1494 10.1185/03007995.2011.597378 10.2174/138161209788923859 10.1016/S0149-2918(01)80072-2 10.1016/j.atherosclerosis.2013.12.004 10.1097/00126097-200408000-00005 10.1161/01.CIR.0000143085.86697.13 |
| ContentType | Journal Article |
| Copyright | 2018 Copyright © 2018. Published by Elsevier Inc. Copyright Elsevier Limited May 2018 |
| Copyright_xml | – notice: 2018 – notice: Copyright © 2018. Published by Elsevier Inc. – notice: Copyright Elsevier Limited May 2018 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88C 88E 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O M7N MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1016/j.clinthera.2018.03.010 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Research Library Prep |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-114X |
| EndPage | 691.e1 |
| ExternalDocumentID | 29673890 10_1016_j_clinthera_2018_03_010 S0149291818301036 1_s2_0_S0149291818301036 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | South Korea |
| GeographicLocations_xml | – name: South Korea |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29B 4.4 457 4G. 53G 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABUWG ABWVN ABXDB ABZDS ACDAQ ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HMCUK HVGLF HZ~ H~9 IHE J1W KOM M0T M1P M2O M41 MO0 N9A NAPCQ O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q38 R2- ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSZ SV3 T5K UHS UKHRP WH7 WOW XOL Z5R ZGI ZXP ~G- ~HD 0SF 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW NCXOZ RIG AAIAV AATCM ABLVK ABYKQ AJBFU LCYCR AAYXX CITATION PUEGO CGR CUY CVF ECM EIF NPM 7XB 8FK K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c510t-7704b6f4d0e417ff7e276c8d2a2064d969ef998e22e4fdaa967e602f90d28e2f3 |
| IEDL.DBID | .~1 |
| ISSN | 0149-2918 1879-114X |
| IngestDate | Thu Oct 02 07:37:19 EDT 2025 Tue Oct 07 06:20:50 EDT 2025 Wed Feb 19 02:33:29 EST 2025 Wed Oct 01 04:58:22 EDT 2025 Thu Apr 24 23:01:45 EDT 2025 Fri Feb 23 02:30:14 EST 2024 Sun Feb 23 10:18:54 EST 2025 Tue Oct 14 19:31:26 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | dyslipidemia telmisartan fixed-dose combination hypertension rosuvastatin calcium |
| Language | English |
| License | Copyright © 2018. Published by Elsevier Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c510t-7704b6f4d0e417ff7e276c8d2a2064d969ef998e22e4fdaa967e602f90d28e2f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 29673890 |
| PQID | 2037414289 |
| PQPubID | 1226358 |
| ParticipantIDs | proquest_miscellaneous_2028972449 proquest_journals_2037414289 pubmed_primary_29673890 crossref_citationtrail_10_1016_j_clinthera_2018_03_010 crossref_primary_10_1016_j_clinthera_2018_03_010 elsevier_sciencedirect_doi_10_1016_j_clinthera_2018_03_010 elsevier_clinicalkeyesjournals_1_s2_0_S0149291818301036 elsevier_clinicalkey_doi_10_1016_j_clinthera_2018_03_010 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-05-01 |
| PublicationDateYYYYMMDD | 2018-05-01 |
| PublicationDate_xml | – month: 05 year: 2018 text: 2018-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Bridgewater |
| PublicationTitle | Clinical therapeutics |
| PublicationTitleAlternate | Clin Ther |
| PublicationYear | 2018 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Kanbay, Yildirir, Bozbas (bib20) 2005; 27 Lim, Shin, Song (bib3) 2011; 34 Benson, Pershadsingh, Ho (bib7) 2004; 43 (bib14) 2002; 106 Rizos, Milionis, Kostapanos (bib19) 2010; 32 Ruilope (bib10) 2011; 27 Law, Wald, Rudnicka (bib11) 2003; 326 Koh, Quon, Han (bib21) 2004; 110 Liu, Zhao, Wei (bib27) 2014; 233 Lacourciere, Krzesinski, White (bib31) 2004; 9 Tonelli, Sacks, Pfeffer (bib25) 2006; 20 Ridker, Danielson, Fonseca (bib32) 2008; 359 Mallion, Siche, Lacourciere (bib17) 1999; 13 Sever, Dahlof, Poulter (bib24) 2003; 361 Mancia, Parati, Revera (bib23) 2010; 340 Kim, Jo, Lee (bib28) 2016; 38 Lee, Sakuma, Ihm (bib4) 2014; 78 Thom, Poulter, Field (bib34) 2013; 310 Nickenig, Sachinidis, Michaelsen (bib5) 1997; 95 White, Littlejohn, Majul (bib16) 2010; 15 Rizos, Elisaf, Liberopoulos (bib9) 2009; 15 Chobanian, Bakris, Black (bib13) 2003; 42 McGill, Reilly (bib15) 2001; 23 Park, Shin, Hong (bib29) 2016; 10 Jones, Davidson, Stein (bib18) 2003; 92 Son, Guk, Kim (bib30) 2016; 38 Rubba, Marotta, Gentile (bib12) 2009; 5 Castellano, Sanz, Penalvo (bib33) 2014; 64 Schupp, Janke, Clasen (bib8) 2004; 109 (bib1) 2013 Dezii (bib6) 2000; 9 Johnson, Pietz, Battleman, Beyth (bib2) 2004; 10 Rizos, Liberopoulos, Tellis (bib26) 2015; 66 Straznicky, Howes, Lam, Louis (bib22) 1995; 75 Thom (10.1016/j.clinthera.2018.03.010_bib34) 2013; 310 Rubba (10.1016/j.clinthera.2018.03.010_bib12) 2009; 5 Lim (10.1016/j.clinthera.2018.03.010_bib3) 2011; 34 Nickenig (10.1016/j.clinthera.2018.03.010_bib5) 1997; 95 Straznicky (10.1016/j.clinthera.2018.03.010_bib22) 1995; 75 Schupp (10.1016/j.clinthera.2018.03.010_bib8) 2004; 109 Rizos (10.1016/j.clinthera.2018.03.010_bib9) 2009; 15 Johnson (10.1016/j.clinthera.2018.03.010_bib2) 2004; 10 Chobanian (10.1016/j.clinthera.2018.03.010_bib13) 2003; 42 (10.1016/j.clinthera.2018.03.010_bib14) 2002; 106 Kanbay (10.1016/j.clinthera.2018.03.010_bib20) 2005; 27 Son (10.1016/j.clinthera.2018.03.010_bib30) 2016; 38 (10.1016/j.clinthera.2018.03.010_bib1) 2013 Park (10.1016/j.clinthera.2018.03.010_bib29) 2016; 10 Benson (10.1016/j.clinthera.2018.03.010_bib7) 2004; 43 McGill (10.1016/j.clinthera.2018.03.010_bib15) 2001; 23 Rizos (10.1016/j.clinthera.2018.03.010_bib26) 2015; 66 Ridker (10.1016/j.clinthera.2018.03.010_bib32) 2008; 359 White (10.1016/j.clinthera.2018.03.010_bib16) 2010; 15 Tonelli (10.1016/j.clinthera.2018.03.010_bib25) 2006; 20 Liu (10.1016/j.clinthera.2018.03.010_bib27) 2014; 233 Lacourciere (10.1016/j.clinthera.2018.03.010_bib31) 2004; 9 Ruilope (10.1016/j.clinthera.2018.03.010_bib10) 2011; 27 Sever (10.1016/j.clinthera.2018.03.010_bib24) 2003; 361 Lee (10.1016/j.clinthera.2018.03.010_bib4) 2014; 78 Jones (10.1016/j.clinthera.2018.03.010_bib18) 2003; 92 Castellano (10.1016/j.clinthera.2018.03.010_bib33) 2014; 64 Mallion (10.1016/j.clinthera.2018.03.010_bib17) 1999; 13 Koh (10.1016/j.clinthera.2018.03.010_bib21) 2004; 110 Dezii (10.1016/j.clinthera.2018.03.010_bib6) 2000; 9 Rizos (10.1016/j.clinthera.2018.03.010_bib19) 2010; 32 Kim (10.1016/j.clinthera.2018.03.010_bib28) 2016; 38 Law (10.1016/j.clinthera.2018.03.010_bib11) 2003; 326 Mancia (10.1016/j.clinthera.2018.03.010_bib23) 2010; 340 |
| References_xml | – volume: 359 start-page: 2195 year: 2008 end-page: 2207 ident: bib32 article-title: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein publication-title: N Engl J Med – volume: 13 start-page: 657 year: 1999 end-page: 664 ident: bib17 article-title: ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension publication-title: J Hum Hypertens – volume: 310 start-page: 918 year: 2013 end-page: 929 ident: bib34 article-title: Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial publication-title: JAMA – volume: 27 start-page: 1673 year: 2011 end-page: 1682 ident: bib10 article-title: Telmisartan for the management of patients at high cardiovascular risk publication-title: Curr Med Res Opin – volume: 42 start-page: 1206 year: 2003 end-page: 1252 ident: bib13 article-title: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure publication-title: Hypertension – volume: 110 start-page: 3687 year: 2004 end-page: 3692 ident: bib21 article-title: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients publication-title: Circulation – volume: 66 start-page: 36 year: 2015 end-page: 42 ident: bib26 article-title: Combining rosuvastatin with angiotensin-receptor blockers of different PPARgamma-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes publication-title: Angiology – volume: 75 start-page: 582 year: 1995 end-page: 586 ident: bib22 article-title: Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension publication-title: Am J Cardiol – volume: 32 start-page: 492 year: 2010 end-page: 505 ident: bib19 article-title: Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study publication-title: Clin Ther – volume: 95 start-page: 473 year: 1997 end-page: 478 ident: bib5 article-title: Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells publication-title: Circulation – volume: 34 start-page: 1323 year: 2011 end-page: 1328 ident: bib3 article-title: Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007 publication-title: Diabetes Care – volume: 78 start-page: 281 year: 2014 end-page: 287 ident: bib4 article-title: Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease publication-title: Circ J – volume: 10 start-page: 926 year: 2004 end-page: 932 ident: bib2 article-title: Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease publication-title: Am J Manag Care – volume: 38 start-page: 1845 year: 2016 end-page: 1857 ident: bib30 article-title: Pharmacokinetic interaction between rosuvastatin, telmisartan, and amlodipine in healthy male Korean subjects: a randomized, open-label, multiple-dose, 2-period crossover study publication-title: Clin Ther – volume: 361 start-page: 1149 year: 2003 end-page: 1158 ident: bib24 article-title: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial publication-title: Lancet – volume: 233 start-page: 291 year: 2014 end-page: 299 ident: bib27 article-title: Treatment with telmisartan/rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17/Treg functional imbalance in hypertensive patients with carotid atherosclerosis publication-title: Atherosclerosis – volume: 15 start-page: 2815 year: 2009 end-page: 2832 ident: bib9 article-title: Are the pleiotropic effects of telmisartan clinically relevant? publication-title: Curr Pharm Des – volume: 92 start-page: 152 year: 2003 end-page: 160 ident: bib18 article-title: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) publication-title: Am J Cardiol – volume: 27 start-page: 297 year: 2005 end-page: 303 ident: bib20 article-title: Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients publication-title: Ren Fail – volume: 340 start-page: c1197 year: 2010 ident: bib23 article-title: Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial publication-title: BMJ – volume: 20 start-page: 560 year: 2006 end-page: 565 ident: bib25 article-title: Effect of pravastatin on blood pressure in people with cardiovascular disease publication-title: J Hum Hypertens – volume: 23 start-page: 833 year: 2001 end-page: 850 ident: bib15 article-title: Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial publication-title: Clin Ther – volume: 9 start-page: 2 year: 2000 end-page: 6 ident: bib6 article-title: A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension publication-title: Manag Care – volume: 109 start-page: 2054 year: 2004 end-page: 2057 ident: bib8 article-title: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity publication-title: Circulation – volume: 106 start-page: 3143 year: 2002 end-page: 3421 ident: bib14 article-title: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report publication-title: Circulation – volume: 10 start-page: 2599 year: 2016 end-page: 2609 ident: bib29 article-title: Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) publication-title: Drug Des Devel Ther – volume: 43 start-page: 993 year: 2004 end-page: 1002 ident: bib7 article-title: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity publication-title: Hypertension – year: 2013 ident: bib1 publication-title: The World Health Report 2013 – volume: 5 start-page: 343 year: 2009 end-page: 352 ident: bib12 article-title: Efficacy and safety of rosuvastatin in the management of dyslipidemia publication-title: Vasc Health Risk Manag – volume: 38 start-page: 2171 year: 2016 end-page: 2184 ident: bib28 article-title: Blood pressure and cholesterol-lowering efficacy of a fixed-dose combination with irbesartan and atorvastatin in patients with hypertension and hypercholesterolemia: a randomized, double-blind, factorial, multicenter Phase III Study publication-title: Clin Ther – volume: 9 start-page: 203 year: 2004 end-page: 210 ident: bib31 article-title: Sustained antihypertensive activity of telmisartan compared with valsartan publication-title: Blood Press Monit – volume: 326 start-page: 1423 year: 2003 ident: bib11 article-title: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis publication-title: BMJ – volume: 64 start-page: 2071 year: 2014 end-page: 2082 ident: bib33 article-title: A polypill strategy to improve adherence: results from the FOCUS project publication-title: J Am Coll Cardiol – volume: 15 start-page: 205 year: 2010 end-page: 212 ident: bib16 article-title: Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension publication-title: Blood Press Monit – volume: 43 start-page: 993 year: 2004 ident: 10.1016/j.clinthera.2018.03.010_bib7 article-title: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity publication-title: Hypertension doi: 10.1161/01.HYP.0000123072.34629.57 – volume: 38 start-page: 2171 year: 2016 ident: 10.1016/j.clinthera.2018.03.010_bib28 article-title: Blood pressure and cholesterol-lowering efficacy of a fixed-dose combination with irbesartan and atorvastatin in patients with hypertension and hypercholesterolemia: a randomized, double-blind, factorial, multicenter Phase III Study publication-title: Clin Ther doi: 10.1016/j.clinthera.2016.09.005 – volume: 34 start-page: 1323 year: 2011 ident: 10.1016/j.clinthera.2018.03.010_bib3 article-title: Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007 publication-title: Diabetes Care doi: 10.2337/dc10-2109 – year: 2013 ident: 10.1016/j.clinthera.2018.03.010_bib1 publication-title: The World Health Report 2013 – volume: 66 start-page: 36 year: 2015 ident: 10.1016/j.clinthera.2018.03.010_bib26 article-title: Combining rosuvastatin with angiotensin-receptor blockers of different PPARgamma-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes publication-title: Angiology doi: 10.1177/0003319713512556 – volume: 326 start-page: 1423 year: 2003 ident: 10.1016/j.clinthera.2018.03.010_bib11 article-title: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis publication-title: BMJ doi: 10.1136/bmj.326.7404.1423 – volume: 75 start-page: 582 year: 1995 ident: 10.1016/j.clinthera.2018.03.010_bib22 article-title: Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension publication-title: Am J Cardiol doi: 10.1016/S0002-9149(99)80621-3 – volume: 15 start-page: 205 year: 2010 ident: 10.1016/j.clinthera.2018.03.010_bib16 article-title: Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension publication-title: Blood Press Monit doi: 10.1097/MBP.0b013e32833c5722 – volume: 95 start-page: 473 year: 1997 ident: 10.1016/j.clinthera.2018.03.010_bib5 article-title: Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells publication-title: Circulation doi: 10.1161/01.CIR.95.2.473 – volume: 27 start-page: 297 year: 2005 ident: 10.1016/j.clinthera.2018.03.010_bib20 article-title: Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients publication-title: Ren Fail doi: 10.1081/JDI-56610 – volume: 340 start-page: c1197 year: 2010 ident: 10.1016/j.clinthera.2018.03.010_bib23 article-title: Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial publication-title: BMJ doi: 10.1136/bmj.c1197 – volume: 42 start-page: 1206 year: 2003 ident: 10.1016/j.clinthera.2018.03.010_bib13 article-title: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure publication-title: Hypertension doi: 10.1161/01.HYP.0000107251.49515.c2 – volume: 92 start-page: 152 year: 2003 ident: 10.1016/j.clinthera.2018.03.010_bib18 article-title: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) publication-title: Am J Cardiol doi: 10.1016/S0002-9149(03)00530-7 – volume: 310 start-page: 918 year: 2013 ident: 10.1016/j.clinthera.2018.03.010_bib34 article-title: Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2013.277064 – volume: 64 start-page: 2071 year: 2014 ident: 10.1016/j.clinthera.2018.03.010_bib33 article-title: A polypill strategy to improve adherence: results from the FOCUS project publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2014.08.021 – volume: 359 start-page: 2195 year: 2008 ident: 10.1016/j.clinthera.2018.03.010_bib32 article-title: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein publication-title: N Engl J Med doi: 10.1056/NEJMoa0807646 – volume: 13 start-page: 657 year: 1999 ident: 10.1016/j.clinthera.2018.03.010_bib17 article-title: ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension publication-title: J Hum Hypertens doi: 10.1038/sj.jhh.1000925 – volume: 10 start-page: 2599 year: 2016 ident: 10.1016/j.clinthera.2018.03.010_bib29 publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S112873 – volume: 10 start-page: 926 year: 2004 ident: 10.1016/j.clinthera.2018.03.010_bib2 article-title: Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease publication-title: Am J Manag Care – volume: 109 start-page: 2054 year: 2004 ident: 10.1016/j.clinthera.2018.03.010_bib8 article-title: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity publication-title: Circulation doi: 10.1161/01.CIR.0000127955.36250.65 – volume: 5 start-page: 343 year: 2009 ident: 10.1016/j.clinthera.2018.03.010_bib12 article-title: Efficacy and safety of rosuvastatin in the management of dyslipidemia publication-title: Vasc Health Risk Manag doi: 10.2147/VHRM.S3662 – volume: 20 start-page: 560 year: 2006 ident: 10.1016/j.clinthera.2018.03.010_bib25 article-title: Effect of pravastatin on blood pressure in people with cardiovascular disease publication-title: J Hum Hypertens doi: 10.1038/sj.jhh.1002036 – volume: 32 start-page: 492 year: 2010 ident: 10.1016/j.clinthera.2018.03.010_bib19 article-title: Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study publication-title: Clin Ther doi: 10.1016/j.clinthera.2010.03.018 – volume: 9 start-page: 2 year: 2000 ident: 10.1016/j.clinthera.2018.03.010_bib6 article-title: A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension publication-title: Manag Care – volume: 38 start-page: 1845 year: 2016 ident: 10.1016/j.clinthera.2018.03.010_bib30 article-title: Pharmacokinetic interaction between rosuvastatin, telmisartan, and amlodipine in healthy male Korean subjects: a randomized, open-label, multiple-dose, 2-period crossover study publication-title: Clin Ther doi: 10.1016/j.clinthera.2016.06.011 – volume: 106 start-page: 3143 year: 2002 ident: 10.1016/j.clinthera.2018.03.010_bib14 article-title: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report publication-title: Circulation doi: 10.1161/circ.106.25.3143 – volume: 361 start-page: 1149 year: 2003 ident: 10.1016/j.clinthera.2018.03.010_bib24 publication-title: Lancet doi: 10.1016/S0140-6736(03)12948-0 – volume: 78 start-page: 281 year: 2014 ident: 10.1016/j.clinthera.2018.03.010_bib4 article-title: Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease publication-title: Circ J doi: 10.1253/circj.CJ-13-1494 – volume: 27 start-page: 1673 year: 2011 ident: 10.1016/j.clinthera.2018.03.010_bib10 article-title: Telmisartan for the management of patients at high cardiovascular risk publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.597378 – volume: 15 start-page: 2815 year: 2009 ident: 10.1016/j.clinthera.2018.03.010_bib9 article-title: Are the pleiotropic effects of telmisartan clinically relevant? publication-title: Curr Pharm Des doi: 10.2174/138161209788923859 – volume: 23 start-page: 833 year: 2001 ident: 10.1016/j.clinthera.2018.03.010_bib15 article-title: Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial publication-title: Clin Ther doi: 10.1016/S0149-2918(01)80072-2 – volume: 233 start-page: 291 year: 2014 ident: 10.1016/j.clinthera.2018.03.010_bib27 article-title: Treatment with telmisartan/rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17/Treg functional imbalance in hypertensive patients with carotid atherosclerosis publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2013.12.004 – volume: 9 start-page: 203 year: 2004 ident: 10.1016/j.clinthera.2018.03.010_bib31 article-title: Sustained antihypertensive activity of telmisartan compared with valsartan publication-title: Blood Press Monit doi: 10.1097/00126097-200408000-00005 – volume: 110 start-page: 3687 year: 2004 ident: 10.1016/j.clinthera.2018.03.010_bib21 article-title: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients publication-title: Circulation doi: 10.1161/01.CIR.0000143085.86697.13 |
| SSID | ssj0003952 |
| Score | 2.3647106 |
| Snippet | Hypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these multiple... AbstractPurposeHypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these... PurposeHypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these multiple... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 676 |
| SubjectTerms | Aged Antihypertensive Agents - therapeutic use Blood pressure Blood Pressure - drug effects Body mass index Calcium Cardiovascular diseases Cholesterol Combination therapy Double-Blind Method Double-blind studies Drug Combinations Drug dosages Dyslipidemia Dyslipidemias - drug therapy Family medical history Female fixed-dose combination Humans Hypertension Hypertension - drug therapy Internal Medicine Lipids Low density lipoprotein Male Metabolic disorders Middle Aged Patients Regression analysis Risk factors rosuvastatin calcium Rosuvastatin Calcium - administration & dosage Safety Statins telmisartan Telmisartan - administration & dosage |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3ri9NAEF_PHohfROuresoKcihkId3sJdkDkVNbeuqV0mvx7lPYJLtcpSZn04rxr3dm8yjC6Qn5ELIzkyaZnf1Ndx6EvDTSC8MYJpIX8IQJkQgWu1qzwBMB9k0LE47JySdjfzQXH88OznbIuMmFwbDKxiZaQ53mCf5HDk66B4sfgGX59vI7w65RuLvatNBQdWuF9I0tMXaT7HKsjNUhu-8G48m0tc2etD140C9gXPbDPyK-MBfRZj1hxFdoa59iYu3V69Xf8Khdl4Z3yZ0aUNKjSgPukR2ddcmtk3rLvEv2J1Vx6tKhs22uVeHQfTrZlq0u79_oDrCaBBBSlaX0VBm9Lmlu6HDxU6cszQtNwXiAI22_ZS2spF8W6ws600vQF9BClVnuaV5sfihMVlpkFI5POWDTjE6qIq5FxTQCF3hlA-jziutDCaC36lirDuls8Pl0dsTO5_QVnDbi2cqKhhEUjckx9Hx-obLXDlXUZhNjuKleOXQKIvNvi186dahg8KQOBW8hXmoWwxeAixPcQYhzVkfrL5EQXgk85_HxMcUAy_IBmQ8Hs_cjVreMYAkYlzX4Cq6IfSNSV4t-YEygeeAnYcoVB-yVSl9qAw6m5lwLkyol_UD7LjfSTTlcNd5D0snyTD8mNE5iERtfBHHfCKAKPeEqbUCnjXfgyX6P-I1iREldTx3beiyjJnDua9RqVIQaFbleBBrVI27LeFmVFLmeJWw0L2oyZsHGR7DsXc8aXMWqi9pWFVE_Knjk2jA_iXMCjDw2__B75LDlrOFYBbP-77Z7zQSJ2jtt53CPvGiHQYFwk0plOt8gDQwHADqB5lE1sdq3xCX2qJXuk38Lf0pu4y-pwlL3SGe92uhnAB3X8fPaHvwG4oNwFQ priority: 102 providerName: ProQuest |
| Title | Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0149291818301036 https://www.clinicalkey.es/playcontent/1-s2.0-S0149291818301036 https://dx.doi.org/10.1016/j.clinthera.2018.03.010 https://www.ncbi.nlm.nih.gov/pubmed/29673890 https://www.proquest.com/docview/2037414289 https://www.proquest.com/docview/2028972449 |
| Volume | 40 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1879-114X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier Science Direct Journals customDbUrl: eissn: 1879-114X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: ACRLP dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1879-114X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection Journals customDbUrl: eissn: 1879-114X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: AIKHN dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1879-114X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: AKRWK dateStart: 19950101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1879-114X dateEnd: 20250905 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1879-114X dateEnd: 20250905 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwEDfTkBAvCMpXYUxGQhNICU0dL072VkarlrGq6lqxPVlOYmtBJZmaFlEe-Nu5y1c1MTQkpKhJ7Tsncc7ns_y7O0LemMD1_RAGkitYZHMecTt0tLaFywXmTfMjhs7Jp2NvOOefzg_Pd8hx7QuDsMpK95c6vdDWVUmn6s3OVZJ0EJYEczvMUL6LyQow7DbnArMYvP-1hXm4QZF1B4ltpL6G8ULvw8LPCTFefhHtFF1pb56h_maBFjPR4CF5UJmQtFc-5SOyo9MWuXdabZK3yMGkDEe9sehs612VW_SATraBqjeP77T6GD8CCKlKY3qmjF5taGboIPmhYzvOck1BXcDSufh6VWMb-iVZXdKZXoCEQE-ptOCeZvn6u0L3pCSlcJxkYI2mdFKGbc1LpiEsepcFZD4ruT5uwMwtc9SqIzrrfz6b9eyLOX0Ll3Xz9rJoGmqwaXSHoRfzS5W-s6iihf8wAkz10qJTaDL7lvzUsUW5DW9qUVgfhAtth_AFoHCCewZhZlf4_AUSQpfAe45GI4qQys0TMh_0Z8dDu0oSYUegTlawOnB46BkeO5p3hTFCM-FFfswUA2srDrxAG1hSasY0N7FSgSe05zATODGDUuM-JbtplurnhIZRyEPjcRF2DQcq3-WO0gak2LiHbtBtE68WDBlVEdQxkcdC1lC5r7KRKIkSJR1XgkS1idMwXpVBRG5n8WvJk7WPLGh1CRPd7aziJladV9opl12ZM-nIP0ZQmxw1nNcG4b_ddq8eILK5E8PwRhjUL2iT1001CBBuS6lUZ2ukgWoBZibQPCsHVtNLLMCstIHz4n-e7CW5j_9KmOoe2V0t1_oVmJKrcL_QFfArzsU-udsbnQzHcP7QH0-mvwFm_XiH |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwEDdjk4AXBOWrMMBIMIFUS6njJfGkCQ3WqWVbVW2t2J6Mk9haUUlG0wHhj-Nv4y5fE9JgvEzKQxT7Lk1yvo_6fneEvLTSDYIQFpLr84gJEQkWOsYw3xU-9k0LIo7g5P2h15-ID0frR0vkV42FwbTKWicWijpOI_yPHIJ0F4wfOMvy7elXhl2jcHe1bqGhq9YK8WZRYqwCduya_DuEcNnmYBu-9yvOd3rj931WdRlgEcjjAtxLR4SeFbFjRNe31jfc96Ig5pqDuY6lJ42FmMRwboSNtZaebzyHW-nEHK5aF_heJyvCFRKCv5V3veHooLEFrix6_mAcwrjsBn9kmCH2sUBZYYZZUNRaRSDvxfbxb_5vYQd37pDblQNLt0qJu0uWTNIiN_arLfoWWRuVxbDzDh2fY7uyDl2jo_My2fm9a60eVq-AiVQnMT3U1ixymlq6M_1hYhanmaGgrCBwL2SnYpbTj9PFCR2bGcgnSL1OCuqDNDv7phEcNU0oHLsp-MIJHZVFY7OSqA8h97xI2E9Lqu0cnOyyQ67eoOPe3uF4ix1P6Gs4rdmzecEaRpA1gnHo8eREJ286VNMCvYzprWbeoQfAMv0y_WniDhUMnrRDIToJZ4aF8AXg4gh3LMKUVeiAGU6EVwLPORgMKCZ05vfJ5EqE5wFZTtLEPCI0jEIRWk_4YdcKmBW4wtHGwhqy7roru23i1YKhoqp-O7YRmak6Ue-zaiRKoUQpx1UgUW3iNISnZQmTy0mCWvJUjdAFm6LAzF5O6l9EarJKN2aqqzKunCKtUOKaAKOCzUa8NtloKCv3r3Tr_u-2q_UCUc2dznVGm7xohkGAcFNMJyY9wzkw7IOTC3MelgureUtcYk9c6Tz-N_Pn5GZ_vL-n9gbD3SfkFv6qMiV2lSwv5mfmKbiti_BZpRso-XTV6ug3J0etEQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFDZjSBMvCMqtMMBIMIFUi9TxkngSQhNt1dJtqrZWdE8mF1srKsloWiD8NH4d5-RWIQ3Gy6Q-VLbPSZN8Ppf6XAh5YaTteQFsJNvlIRMiFCywtGauLVzsm-aFHJOTD4-c_kR8mO5ON8ivKhcGwyormZgL6igJ8T9ycNJtUH5gLMs3pgyLGHV6786_MuwghSetVTuNAiJDnX0H9y19O-jAu37Jea87ft9nZYcBFgIWl2BaWiJwjIgsLdquMa7mrhN6Efc5qOpIOlIb8Ec051qYyPel42rH4kZaEYdRYwPf6-SGa9sSwwndae3sWTDCi_BJybhse3_ElmHWY55fhbFlXl5lFVN4L9aMf7N8cw3Yu01ulaYr3S-wdods6LhBtg7Lw_kG2RkVZbCzFh2vs7rSFt2ho3WB7OzutUYX61bAQurHET3xjV5mNDG0N_uhIxYlqaYgpsBlz1FTMsvox9nyjI71HJAJePfjnPo4SVfffEyLmsUUPsMErOCYjopysWlB1Adne5GH6icFVScD87rojevv0XH34GS8z04n9BV8rdizRc4aZpA1puHQ08mZH79uUZ_mecsY2KoXLXoMLJMvs586alHB4E5bFPySYK5ZAG8ABkd4VhEkrMwLmONCeCRwn4PBgGIoZ3aPTK4EOvfJZpzE-iGhQRiIwDjCDdpGwCrPFpavDeweY-_ast0kTgUMFZaV27GByFxVIXqfVY0ohYhSlq0AUU1i1YTnRfGSy0m8Cnmqys0FbaJAwV5O6l5EqtNSKqaqrVKurDygUOKeAHWCbUacJtmrKUvDrzDo_u-y29UGUfWV1tKiSZ7X0wAgPA7zY52scA1Mu2DewpoHxcaqnxKX2A1XWo_-zfwZ2QIhpA4GR8PH5Cb-qCIWdptsLhcr_QTs1WXwNBcMlHy6akn0G3Usqqs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+Safety+of+Fixed-dose+Combination+Therapy+With+Telmisartan+and+Rosuvastatin+in+Korean+Patients+With+Hypertension+and+Dyslipidemia%3A+TELSTA-YU+%28TELmisartan-rosuvaSTAtin+from+YUhan%29%2C+a+Multicenter%2C+Randomized%2C+4-arm%2C+Double-blind%2C+Placebo-controlled%2C+Phase+III+Study&rft.jtitle=Clinical+therapeutics&rft.au=Oh%2C+Gyu+Chul&rft.au=Han%2C+Jung-Kyu&rft.au=Han%2C+Ki+Hoon&rft.au=Hyon%2C+Min-Su&rft.date=2018-05-01&rft.pub=Elsevier+Inc&rft.issn=0149-2918&rft.volume=40&rft.issue=5&rft.spage=676&rft.epage=691.e1&rft_id=info:doi/10.1016%2Fj.clinthera.2018.03.010&rft.externalDocID=S0149291818301036 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291818X00058%2Fcov150h.gif |